Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

Sign up for The Fulcrum newsletter

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.

Read More

Houses with price tags
retrorocket/Getty Images

Are housing costs driving inflation in 2024?

This fact brief was originally published by EconoFact. Read the original here. Fact briefs are published by newsrooms in the Gigafact network, and republished by The Fulcrum. Visit Gigafact to learn more.

Are housing costs driving inflation in 2024?

Yes.

The rise in housing costs has been a major source of overall inflation, which was 2.9% in the 12 months ending in July 2024.

The Bureau of Labor Statistics' shelter index, which includes housing costs for renters and homeowners, rose 5.1% in the 12 months ending in July 2024.

Keep ReadingShow less
I Voted stickers
BackyardProduction/Getty Images

Voters cast ballots based on personal perceptions, not policy stances

The Fulcrum and the data analytics firm Fidelum Partners have just completed a nationally representative study assessing the voting intentions of U.S adults and their perceptions toward 18 well-known celebrities and politicians.

Fidelum conducted similar celebrity and politician election studies just prior to the 2016 and 2020 presidential elections. Each of these found that perceptions of warmth, competence and admiration regarding the candidates are highly predictive of voting intentions and election outcomes. Given this, The Fulcrum and Fidelum decided to partner on a 2024 celebrity and politician election study to build upon the findings of prior research.

Keep ReadingShow less
Hand waving an American flag

"Freedom, a word that should inspire, has been distorted to justify the unchecked pursuit of individual interests at the expense of collective well-being," writes Johnson.

nicoletaionescu/Getty Images

Redefining America's political lingua franca

Johnson is a United Methodist pastor, the author of "Holding Up Your Corner: Talking About Race in Your Community" and program director for the Bridge Alliance, which houses The Fulcrum.

A seismic shift has occurred in America's race, identity and power discourse. Like tectonic plates beneath the Earth's surface, long-held assumptions are adjusting and giving way to a reimagined lingua franca for civic engagement. This revived language of liberation redefines the terms of debate. It empowers us to reclaim and reinvigorate words once weaponized principally against marginalized communities.

Keep ReadingShow less
Latino attendees of the Democratic National Convention

People cheer for the Harris-Walz ticket at the Democratic National Convention.

Robert Gauthier/Los Angeles Times via Getty Images

Harris’ nomination ‘hit a reset button’ for Latinas supporting Democrats

As the presidential race entered the summer months, President Joe Biden’s level of support among Latinx voters couldn’t match the winning coalition he had built in 2020. Among Latinas, a critical group of voters who tend to back Democrats at higher levels than Latinos, lagging support had begun to worry Stephanie Valencia, who studies voting patterns among Latinx voters across the country for Equis Research, a data analytics and research firm.

Then the big shake-up happened: Biden stepped down and Vice President Kamala Harris took his place at the top of the Democratic ticket fewer than 100 days before the election.

Valencia’s team quickly jumped to action. The goal was to figure out how the move was sitting with Latinx voters in battleground states that will play an outsized role in deciding the election. After surveying more than 2,000 Latinx voters in late July and early August, Equis found a significant jump in support for the Democratic ticket, a shift that the team is referring to as “the Latino Reset.”

Keep ReadingShow less